Publisher's Note: New mobile edition!

Publisher's Note: New mobile edition!

We've been fielding a number of requests to make the newsletters easier to read, particularly on mobile devices. Today I'm pleased to announce the launch of our new mobile application. The Fierce Mobile service is an on-device application that gives you real-time access to news feeds from all of our Life Science publications, and can also be used as your default mobile RSS reader. You can add feeds from the WSJ, CNN, local weather or any other news outlet or blog. The application is compatible with Blackberry, Windows Mobile, Symbian and Palm devices and will soon support the iPhone.

The app can be installed by going to the following URL on your mobile phone's browser--http://fb.mwap.at. Follow the simple download instructions from there. I want to give a special thanks to FreeRange Communications, the company powering FierceBiotech Mobile and our other mobile editions.

As a confessed Blackberry addict, I personally love the new application. I'm confident that you will, too. Check it out!

Thanks to everyone in the community for the continued feedback that led to our new mobile edition. As always, feel free to contact me with any questions, complaints or ideas.

Best,

Sean Griffey
Publisher, FierceBiotech and FiercePharma

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.